Welcome to our dedicated page for Ardent Health SEC filings (Ticker: ARDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardent Health, Inc. (NYSE: ARDT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Ardent Health is a healthcare company in the medical care facilities industry that operates 30 acute care hospitals and approximately 280 sites of care across six states, and its filings offer detailed information on its financial condition, capital structure, governance and material events.
Among the key documents available are Current Reports on Form 8-K, where Ardent Health reports significant developments. Recent 8-K filings describe quarterly financial results, including the release of earnings for specific quarters and the use of non-GAAP measures such as Adjusted EBITDA and Adjusted EBITDAR. These filings often incorporate the related earnings press release as an exhibit, providing definitions of non-GAAP metrics, reconciliations to GAAP measures and discussions of operating metrics like admissions, surgeries and net patient service revenue per adjusted admission.
Other 8-K filings detail financing and capital structure actions. For example, Ardent Health has reported amendments to its Amended and Restated Term Loan Credit Agreement and its Amended and Restated ABL Credit Agreement, extending term loan maturities, adjusting interest rate spreads over Term SOFR and the base rate, and updating baskets for certain negative covenants. Another 8-K describes the authorization of a stock repurchase program of up to $50.0 million of the company’s common stock, including the potential use of open market purchases, privately negotiated transactions, block trades and Rule 10b5-1 plans.
Filings also cover governance and executive matters, such as leadership changes and the treatment of departures under the company’s Executive Severance Plan. References to proxy statements and severance plan documents in these filings point investors to additional information on executive compensation and severance arrangements.
On Stock Titan, these ARDT filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the substance of each filing, highlight key terms in credit agreements, clarify the implications of non-GAAP metrics and stock repurchase authorizations, and make it easier to understand how individual disclosures relate to Ardent Health’s hospital operations and financial profile.
Ardent Health, Inc. announced that its board of directors has authorized a stock repurchase program for up to $50.0 million of its common stock. The program has no specified expiration date, giving the company flexibility in timing any buybacks. Repurchases may be made through open market purchases, privately negotiated transactions, block trades or other transactions in line with applicable securities laws, including the pricing and volume requirements of Rule 10b-18 under the Exchange Act.
Ardent may also use Rule 10b5-1 plans to facilitate repurchases. The company is not obligated to repurchase any specific amount of shares and can modify, suspend or terminate the program at any time. It expects to fund any repurchases with existing cash and cash equivalents and ongoing cash from operations.
Ardent Health, Inc. reported Q3 2025 results with total revenue of
For the first nine months, revenue reached
Ardent refinanced its Term Loan B on
Ardent Health, Inc. (ARDT) furnished its third-quarter 2025 results press release. The company reported that, on November 12, 2025, it issued a press release covering financial results for the quarter ended September 30, 2025, and made it available as Exhibit 99.1 to a current report on Form 8-K under Item 2.02.
The information provided under Item 2.02, including Exhibit 99.1, is furnished rather than filed, meaning it is not subject to Section 18 of the Exchange Act and will only be incorporated by reference into other filings if expressly stated. The filing also lists Exhibit 104 for the cover page interactive data file. This is a routine disclosure that makes the company’s quarterly results press release part of the public record without triggering the liabilities associated with filed materials.
Ardent Health, Inc. (ARDT) Form 4: Chief Financial Officer Alfred Lumsdaine reported a transaction on 09/25/2025 in which 3,389 shares of the issuer's common stock were disposed of at a price of $13.19 per share. The filing states the shares were withheld to pay taxes upon vesting of restricted stock units. After the reported disposition, the reporting person beneficially owns 211,147 shares, held directly. The form was signed by an attorney-in-fact on 09/30/2025.
Stephen C. Petrovich, Executive Vice President, General Counsel and Assistant Secretary of Ardent Health, Inc. (ARDT), reported a routine share disposition on 09/25/2025. The filing shows 788 shares were withheld to satisfy tax withholding upon vesting of restricted stock units at a closing price of $13.19, and after that transaction Mr. Petrovich directly beneficially owned 718,303 shares. In addition, the filing discloses two family trusts each holding 186,225 shares, which the reporting person disclaims beneficial ownership of except for any pecuniary interest. The form is a standard Section 16 report documenting an internal tax-related share settlement rather than an open-market sale.
David Raynor Byers, Senior Vice President & Chief Accounting Officer of Ardent Health, Inc. (ARDT), reported a routine disposition of common stock on 09/25/2025. The filing shows 524 shares were disposed under Code F (withholding to pay taxes upon vesting of restricted stock units) at a reported price equal to the closing stock price on 09/25/2025 of $13.19. After the withholding, Mr. Byers beneficially owns 111,791 shares directly. The Form 4 was signed by an attorney-in-fact on 09/30/2025.
Ardent Health, Inc. amended its term loan and ABL credit facilities with Bank of America and other lenders. The Term Loan Amendment refinanced outstanding term loans in full, extended the term loan maturity from August 24, 2028 to September 18, 2032, reduced the applicable interest spread by 50 basis points (from Term SOFR+2.75% to Term SOFR+2.25%, and from base rate+1.75% to base rate+1.25%), and expanded fixed-dollar negative covenant baskets. The ABL Amendment aligned certain fixed-dollar negative covenant baskets with the term loan changes but did not extend the ABL maturity or make other material changes. The full amendment texts are filed as exhibits and govern the detailed terms.
Ardent Health, Inc. operates a network of 30 acute care hospitals and approximately 280 sites of care across six states with 1,875 employed and affiliated providers as of June 30, 2025. The company uses a joint-venture model in which it is typically the majority owner and day-to-day operator, partnering with academic and not-for-profit systems to expand market presence and clinical services. EGI-AM Investments, L.L.C. owned approximately 54.0% of outstanding common stock, making EGI-AM the company’s controlling stockholder under NYSE rules. The filing discloses a table of selling stockholders showing large share blocks (for example, 77,246,499 shares representing 54.0%) and various other holders with specified share counts and percentages. The prospectus lists exhibits, underwriting and legal opinions, audit consents from Ernst & Young LLP, and a registration fee table.